Intravenous and oral propafenone for treatment of tachycardia in infants and children: Pharmacokinetics and clinical response

Journal of Clinical Pharmacology

Volumn 38, Issue 6, 1998, Pages 496-501

  Ito, Shinya ^a   Gow, Robert ^a   Verjee, Zul ^a   Giesbrecht, Ester ^a   Dodo, Hidemi ^a   Freedom, Robert ^a   Tonn, George R ^b   Axelson, James E ^b   Zalzstein, Eli ^a   Rosenberg, Herschel C ^c   Koren, Gideon ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c CHILDREN S HOSPITAL OF WESTERN ONTARIO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

5 HYDROXYPROPAFENONE; PROPAFENONE;

ARTICLE; CHILD; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG EFFICACY; ELECTROCARDIOGRAM; FEMALE; HUMAN; INFANT; INTRAVENOUS DRUG ADMINISTRATION; MALE; NEWBORN; ORAL DRUG ADMINISTRATION; QRS COMPLEX; TACHYCARDIA;

EID: 0031782407     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.1552-4604.1998.tb05786.x     Document Type: Article

References (15)

1. Garson A Jr, Moak JP, Smith RT Jr, Norton JB Jr: Usefulness of intravenous propafenone for control of postoperative junctional ectopic tachycardia. Am J Cardiol 1987;59:1422-1424.
2. Koike K, Hesslein PS, Finlay CD, Williams WG, Izukawa T, Freedom RM: Atrial automatic tachycardia in children. Am J Cardiol 1988;61:1127-1130.
3. Guccione P, Drago F, Di Donato RM, Cicini MP, Pasquini L, Marino B, et al: Oral propafenone therapy for children with arrhythmias: efficacy and adverse effects in midterm follow-up. Am Heart J 1991;122:1022-1027.
4. Janousek J, Paul T, Reimer A, Kallfelz H-C: Usefulness of propafenone for supraventricular arrhythmias in infants and children. Am J Cardiol 1993;72:294-300.
5. Bauersfeld U, Gow RM, Hamilton RM, Izukawa T: Treatment of atrial ectopic tachycardia in infants <6 months old. Am Heart J 1995;129:1145-1148.
6. Dodo H, Gow RM, Hamilton RM, Freedom RM: Chaotic atrial rhythm in children. Am Heart J 1995;129:990-995.
7. Siddoway LA, Thompson KA, McAllister CB, Wang T, Wilkinson GR, Roden DM, Woosley RL: Polymorphism of propafenone metabolism and disposition in man: clinical and pharmacokinetic consequences. Circulation 1987;75:785-791.
8. Thompson KA, Ian Smith DH, Siddoway LA, Wooseley RL, Roden DM: Potent electrophysiologic effects of the major metabolites of propafenone in canine Purkinje fibers. J Pharmacol Exp Ther 1988;244:950-955.
9. Haefeli EW, Vozeh S, Ha H-R, Follath F: Comparison of the pharmacodynamic effects of intravenous and oral propafenone. Clin Pharmacol Ther 1990;48:245-254.
10. Lee JT, Kroemcr HK, Silberstein DJ, Funck-Brentano C, Lineberry MD, Wood AJ, et al: The role of genetically determined polymorphic drug metabolism in the beta-blockade produced by propafenone. N Engl J Med 1990;322:1764-1768.
11. Agúndez JA, Ledesma MC, Ladero JM, Benitez J: Prevalence of CYP2D6 gene duplication and its repercussion on the oxidative phenotype in a white population. Clin Pharmacol Ther 1995;57: 265-269.
12. Ratanasavanh D, Beaune P, Morel F, Flinois J-P, Guengerich FP, Guillouzo A: Intralobular distribution and quantitation of cytochrome P-450 Enzymes in human liver as a function of age. Hepatology 1991;13:1142-1151.
13. Verjee Z, Giesbrecht E: An HPLC method for the quantitation of propafenone and its metabolites in pediatric samples. In, Sunshine I (ed.): Recent Developments in Therapeutic Drug Monitoring and Clinical Toxicology. New York: Marcel Dekker, 1992;383-388.
14. Koren G, Beatie D, Soldin J, Einarson T, MacLeod SM: Interpretation of high postmortem concentrations of digoxin in children. Arch Pathol Lab Med 1989;113:758-761.
15. Koren G, Klein J: Postmortem redistribution of morphine in rats. Ther Drug Monit 1992;14:461-463.